This is a repository copy of Classification of neuropathic pain in cancer patients.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/87653/

Version: Accepted Version

Article:
Boland, EG, Mulvey, MR and Bennett, MI (2015) Classification of neuropathic pain in cancer patients. Current Opinion in Supportive and Palliative Care, 9 (2). pp. 112-115. ISSN 1751-4258

https://doi.org/10.1097/SPC.0000000000000136

Reuse
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Classification of neuropathic pain in cancer patients

E.G. Boland¹, M. Mulvey², M.I. Bennett²

¹Queen’s Centre for Oncology and Haematology, Hull and East Yorkshire Hospitals NHS Trust and Hull York Medical School, University of Hull, UK.
²Academic Unit of Palliative Care, Leeds Institute of Health Sciences, University of Leeds, UK.

Corresponding Author:
Dr Elaine Boland
Consultant in Palliative Medicine and Honorary Senior Lecturer
Queen’s Centre for Oncology and Haematology,
Hull and East Yorkshire Hospitals NHS Trust
Cottingham, UK
T = +44 (0) 1482461303
E = elaine.boland@hey.nhs.uk
Abstract

Purpose of review: Neuropathic pain can affect up to 40% in patients with cancer, which could be related to the tumour, treatment or from co-morbid diseases. Effective assessment to diagnose neuropathic pain is crucial in order to choose the right treatment. Recent findings: There is to date no systematic classification system; the Neuropathic Pain Special Interest Group of the International Association for the Study of Pain developed a neuropathic pain grading system intended to be used for both clinical and research purposes and a recent review describe a step-by-step process for applying the grading system in a clinical setting for cancer pain. Summary: We have combined these recommendations to outline a clinically relevant process to classify NP in patients with cancer.

Keywords

Cancer, pain, neuropathic, assessment
Introduction

Neuropathic pain (NP) arises due to a disease or a lesion affecting the somatosensory system and can thus arise from pathology affecting either the peripheral or the central nervous system [1]. Neuropathic pain is a heterogeneous entity with various clinical key findings including spontaneous pain, which can either be continuous or dominated by paroxysms of pain. Patients may also complain of loss of sensation (numbness) or experience pain evoked by non-noxious triggers such as light brushing or cold leading to allodynia [2]. Patients with such pain may express different combinations of these symptoms. The sensations from NP can be unusual and difficult to describe; therefore many patients will neglect to report these symptoms unless prompted by their clinicians [3].

Cancer patients experience NP which can be tumour-related, treatment-related (particularly post-surgical or post-chemotherapy) or from co-morbid diseases such as diabetic neuropathy. Tumour-related neuropathic pain is often multifactorial and involves a combination of inflammatory and neuropathic mechanisms; the magnitude and relative contribution of these change as the tumour advances [4]. This classification of NP in cancer patients will be reflected in a forthcoming 11th revision of the International Classification of Diseases by the World Health Organization [5].

About 20% of pains in cancer patients are neuropathic but about 40% of patients are affected by NP because each patient experiences two pains on
Cancer patients with NP have been shown to have poorer cognitive, physical and social functioning than patients without NP features, which has a greater impact on their daily living. For this reason, it is seen as a core component with a cancer pain classification system.

Some cases of neuropathic conditions are straightforward, such as patients with malignant spinal cord compression where motor and sensory changes can be detected on clinical assessment and directly visualized on magnetic resonance imaging. However, such scenarios are the exception rather than the rule. Other clinical conditions, such as metastatic bone disease, result in more of a mixed picture. The challenge is to discriminate NP from other types of pain in cancer patients and to identify the lesion or disease causing the pain. The demonstration of abnormal function in the somatosensory system, including negative (hypoesthesia and hypoalgesia) and positive (allodynia and hyperalgesia) sensory phenomena can contribute towards a diagnosis of NP.

A recent systematic literature review on NP in cancer patients based on 22 studies demonstrated that clinical assessment methods varied and thus a standardised approach for assessing NP in cancer is needed to improve treatment outcomes. Effective assessment to diagnose NP in cancer patients is crucial in order to choose the right analgesic interventions, as these will vary depending on the nature and aetiology of the pain.
Pathophysiology of NP

The pathophysiology of NP is incompletely understood. Following a peripheral nerve injury, A-δ fibre and C-fibre primary afferent neurons become abnormally sensitive and develop pathological spontaneous activity, which leads to peripheral sensitisation. This triggers expression of sodium and calcium channels, release of various receptor proteins, and growth factors from degenerating nerve fibres. This activity provokes secondary changes in central sensory processing, leading to spinal cord hyper-excitability and central sensitisation [10]. The descending pathways also exacerbate dorsal horn excitation after peripheral nerve injury, as there is an increase in descending excitatory activity from the brainstem, as well as a reduction of descending inhibitory controls [11].

Grading system for neuropathic pain

Despite the clinical significance of NP, there is, to date, no systematic classification system, and in particular there is uncertainty surrounding the diagnosis of NP in cancer patients. This situation is likely to inhibit improvements in treatments and outcomes [12]. Standardised classification of neuropathic pain would enable more accurate diagnosis for epidemiology, health management and clinical purposes and attempt to guide the translation of results from clinical trials into clinical practice [13].
The Neuropathic Pain Special Interest Group (NeuPSIG) of the International Association for the Study of Pain developed a NP grading system intended to be used for both clinical and research purposes [1].

Four specific criteria used are summarised in Table 1. To consider possible neuropathic pain, criteria 1 and 2 must be met whilst criterion 3 or 4 must be met for diagnosing probable NP. If all 4 criteria are satisfied, the diagnosis of definite NP is reached.

Despite this grading system, there is still no standardised guidance on the implementation of this, particularly on the confirmatory tests (criterion 3), which may explain why there has been poor use of this system both in clinical practice and in the research setting. Recently, two papers have examined how to adapt the NeuPSIG grading system for patients with cancer pain [12, 14].

Mulvey et al. (2014) describe a step-by-step process for applying the grading system in a clinical setting for cancer pain, including the procedure for demonstrating sensory abnormalities. Applying the grading system in clinical practice is relatively straightforward and simple as some tests may serve a dual purpose. For example, determining the distribution of pain (criterion 1) by the use of toothpick or soft brush to delineate an area of hyperalgesia or allodynia, one can also confirm the presence sensory abnormalities (criterion 3). Likewise, criteria 2 and 4 may be met simultaneously by the use of a CT scan showing tumour growth compressing a nervous structure innervating the
relevant painful region. This demonstrates a history of a relevant disease/lesion (criterion 2) and provides an additional objective confirmatory test (criterion 4).

A recent Delphi survey about the use and adaptation of the NeuPSIG criteria for NP diagnosis to be applied in cancer patients was conducted where an international group of 29 experts participated; the results showed experts agreed on criteria 1-3 of the NeuPSIG, whereas for the fourth criteria (confirmation of lesion affecting the somatosensory system from diagnostic test or imaging) experts suggested that a distinction had to be made whether history and existing exams could explain the cause of the pain [14]. We have combined these recommendations to outline a clinically relevant process to classify NP.

**Recognising neuropathic pain (Criteria 1 and 2)**

This process involves identifying cancer patients with painful symptoms that match a neuroanatomical pattern. The cause of the pain needs to be established by distinguishing between cancer-related and/or treatment-related or comorbid causes in order to demonstrate a history suggestive of a lesion or disease affecting the somatosensory system.

A detailed history taking should include asking specific questions about pain characteristics, location and radiation and also reviewing oncological and general medical records. Drawing the location of pain on a body-map can be
a useful tool to indicate the distribution of pain and consider whether it is neuro-anatomically plausible. Specific screening tools help to identify patients with possible NP and may be included as part of the clinical assessment, however such tools are not intended to be diagnostic methods. Examples of screening tools that aid identification are the Leeds assessment of neuropathic symptoms and signs (LANSS) pain scale, the painDETECT questionnaire, and Douleur neuropathique (DN4). The main advantage of such screening tools is that they can easily identify individuals with possible neuropathic pain in a variety of settings.

Confirmatory and diagnostic tests (Criteria 3 and 4)

A systematic search for neurological abnormalities is necessary to identify a lesion in the somatosensory system. Clinical examination, specifically looking for sensory signs, accepts or rejects the hypothesis of possible neuropathic pain that has been based on the history. Bedside tests of somatosensory functions (Criterion 3) can help identify sensory abnormalities, however this simple testing on its own has a low power of distinguishing neuropathic pain from non-neuropathic pain. The sensory phenomena to examine include: light touch using a cotton bud tip or soft brush, pinprick using a monofilament or a toothpick, vibration using tuning fork, deep pressure using examiners’ thumb, painfully cold & hot thermo rollers or test tubes. Responses should be compared with a non-painful adjacent or contralateral area to establish alterations in sensory function. These tests would highlight a decreased or increased sensitivity (hypo- or hyperphenomena) thus demonstrating altered
sensory processing and should be consistent with the distribution of the pain. Only one sensory abnormality needs to be present to meet the requirement.

In a clinical research context, a more robust laboratory test for Criterion 3 would include quantitative sensory testing; a psychophysical technique requiring co-operation from the patient measuring warmth (a C fibre–mediated sensation), cooling (an Aδ-mediated sensation), and vibration (a sensation mediated by large, myelinated Aβ afferents). If the result for one or more of these sensory tests are abnormal, it may imply that there is a signal dysfunction along the sensory pathways anywhere between the receptors, the sensory or associated cortices [20].

To confirm the presence of a lesion affecting the somatosensory system, imaging such as magnetic resonance imaging or computed tomography imaging should be requested, if not already present in the patient’s notes (Criterion 4).

The evaluation of NP in cancer patients is summarised in Table 2.

Discussion

Cancer-related NP is often undiagnosed and is accompanied by disability, poor quality of life, distress and increased cost to the healthcare system. Assessment and classification of pain should be a fundamental part of the management to control cancer pain [21].
When a patient presents with pain in clinical practice, questioning the patient about the symptoms and performing an examination together with use of screening tools might alert the physician that the pain could probably be neuropathic. There is still no gold standard for diagnosing NP; nevertheless, the NeuPSIG grading system is beneficial for robust assessment of NP. However, the patient population needs to be specified as has been described by Mulvey et al in the adapted version of the NeuPSIG grading system for cancer pain [9, 12].

Conclusion

Despite the increased recognition of neuropathic pain in cancer and non-cancer classifications systems, there remain several important clinical and research questions. Firstly, what role do neuropathic pain symptom screening tools have in establishing possible neuropathic pain as part of the NP grading system? Secondly, is the number of positive confirmatory tests from criterion 3 and 4 of the grading system associated with a spectrum of symptom severity? Thirdly, does a rigorously applied standardised grading system, including demonstration of sensory abnormalities, lead to more robust diagnosis and ultimately improved treatment outcomes for patients?

Financial support and sponsorship: None

Conflicts of interest statement

All authors declare no conflicts of interest with this manuscript and its content.
**Key points**

- Neuropathic pain arises due to a disease or a lesion affecting the somatosensory system.

- Neuropathic pain in patients with cancer is common and can have an effect on their cognitive, physical and social functioning.

- Existing gold standard assessment can be adapted to cancer patients.

- Better classification of cancer NP will improve clinical practice and research.

**References**


